Table 1.

Summary of tyrosine kinase inhibitors

Characteristics	Imatinib	Dasatinib	Nilotinib	Bosutinib	Ponatinib	Radotinib
Tab strength	100 mg,400 mg	20 mg,50 mg, 70 mg,	50 mg,150 mg,200 mg	100 mg,	15 mg, 45 mg	100 mg,
		80 mg,100 mg, 140 mg		500 mg		200 mg
Adult dose
CML-CP	400 mg OD	100 mg OD	300 mg BD	500 mg OD	45 mg OD	300 mg BD
CML-AP	400 mg BD	140 mg OD	400 mg BD	500 mg OD	Approved for T315I mutation	400 mg BD
CML-BC	400 mg BD	140 mg OD	400 mg BD	500 mg OD		400 mg BD
Pediatric Dose				Not approved	Not approved	Not approved
CML-CP	340 mg/sqm OD	60 mg/sqm OD	230 mg/sqm BD
CML-AP	400 mg/sqmOD	80 mg/sqm OD	230 mg/sqm BD
CML-BC	500 mg/sqmOD	80 mg/sqm OD	230 mg/sqm BD
Interaction with food	Taken with food	No interaction	Two hour before or one hour after food	Taken with food	No interaction	Not known
Common adverse effect	Fluid retention, Myalgia, arthralgia,GI-related, cytopenia	Pleural effusion,	Hyperlipidemia, hyperglycemia, myocardial infarction, stroke,peripheral artery occlusion, pancreatitis, QT prolongation	Diarrhea, elevated liver enzymes	Hypertension,	Myelosuppression, hepatotoxicity, hyperglycemia
		Pulmonary artery hypertension,cytopenia Bleeding/platelet dysfunction			Abdominal pain,
					Arterial thrombosis.hepatotoxicity
Contraindication	None	None	Hypokalemia,hypomagnesemia, prolonged QT interval	Hypersensitivity	None	None
					Black box warning for arterial thrombosis, hepatotoxicity
Drug interaction	Increased exposure:	Increased exposure:	Increased exposure:	Increased exposure:	Increased exposure:	Data not available
	PPI,quinolones,azoles, CSA, valproic acid	PPI, Beta blocker,ACE inhibitor, macrolide,azole, CSA	Macrolides, valproic acid, cyclosporine,azoles	Azoles	Azole, protease inhibitor, macrolide, SRI
	Decreased exposure:	Decreased exposure:	Decreased exposure:	Decreased exposure:	Decreaed exposure:
	Dexamethosone, rifampicin, protease inhibitor, phenytoin carbamazepine, lamivudine,metformin	Dexamethasone, phenytoin, carbamazepine	Dexamethasone, phenytoin, carbamazepine, rifampicin	PPI, rifampicin	Rifampicin, carbamazepine, phenytoin
			Drugs prolonging QT interval has additive effect
Female of childbearing age	Contraception advised	Contraception advised	Contraception advised	Contraception advised	Contraception advised	Data not available
Breast feeding	Contraindicated	Contraindicated	Contraindicated	Contraindicated	Contra-indicated	Data not available

ACE angiotensin converting enzyme, AP accelerated phase, BC blast crisis, BD twice daily, CML chronic myeloid leukemia, CSA cyclosporine, GI gastrointestinal, OD once daily, PPI proton pump inhibitor, SRI serotononin reuptake inhibitor